Two small case series of platelet mitochondrial complex I activity assays in Huntington's Disease (HD) report discrepant results. We measured platelet complex I and complex I/III activity in 21 subjects with early gene-positive HD and 14 age-matched controls. The 21 participants with HD that we studied are greater than the total of 16 in the two previously published of platelet ETS activity in HD. Reductions > 10% were excluded with 80% confidence. A systemic defect in complex I activity is not present in early HD when striatal neuronal degeneration is already present.
Introduction
Abnormalities in mitochondrial function have been described in Huntington's Disease (HD) and implicated in the pathogenesis of the progressive neuronal degeneration (Browne and Beal, 2004; Zeevalk et al., 2005; Orth and Schapira, 2001). In two previous studies of mitochondrial electron transport system (ETS) activity in platelets from patients with HD, one reported a reduction of complex I activity of 72% in five subjects whereas the other reported no significant difference in complex I or complex II/III activity in 11 subjects (Gu et al., 1996; Parker et al., 1990). To clarify this reported discrepancy, we undertook a further study of platelet complex I activity in HD in a larger sample.
Materials and methods

Participants Huntington's Disease
Participants with HD were recruited from the Washington University Movement Disorders Center and through the Huntington's Disease Society of America.
Inclusion criteria were:
1. Previous gene testing with greater than 38 CAG repeats of one allele for IT15. 2. Self-reported symptoms either absent or present for duration of less than 4 years.
Exclusion criteria were:
